v3.25.2
Revenue Recognition (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2023
USD ($)
item
Feb. 28, 2019
USD ($)
Jun. 30, 2025
USD ($)
$ / shares
Jun. 30, 2024
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
$ / shares
Jun. 30, 2024
USD ($)
$ / shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Increased (decreased) revenues         $ (5,800) $ (5,200)    
(Increased) decreased net loss         $ (5,800) $ (5,200)    
(Increased) decreased net loss per share | $ / shares         $ (0.04) $ (0.04)    
Other assets     $ 41,118   $ 41,118   $ 36,720  
Deferred revenue     38,052 $ 36,783 $ 38,052 $ 36,783 36,592 $ 35,740
Product                
Approximate percentage of revenue collected within 9 months         90.00%      
Billing collection period (in months)         9 months      
Extended billing collection period (in months)         6 months      
Increased (decreased) revenues     (3,100) (3,400)        
(Increased) decreased net loss     $ (3,100) $ (3,400)        
(Increased) decreased net loss per share | $ / shares     $ (0.02) $ (0.03)        
Tests delivered in prior periods that were fully collected                
Increased (decreased) revenues     $ 45,300 $ 39,900 $ 79,600 73,700    
(Increased) decreased net loss     $ 45,300 $ 39,900 $ 79,600 $ 73,700    
(Increased) decreased net loss per share | $ / shares     $ 0.33 $ 0.32 $ 0.59 $ 0.6    
Amounts not refunded to insurance carriers                
Increased (decreased) revenues     $ 400 $ 600 $ 900 $ 4,100    
(Increased) decreased net loss per share | $ / shares     $ 0.01 $ 0.01 $ 0.01 $ 0.03    
BGI Genomics                
Revenue recognized   $ 44,000            
Agreement term   10 years            
Revenue, remaining performance obligation   $ 6,000            
Transaction price   50,000            
Deferred revenue     $ 17,000   $ 17,000   $ 17,300  
Prepaid royalties   $ 20,000            
BGI Genomics | License and related development services                
Number of performance obligations | item 2              
Revenue, remaining performance obligation $ 24,000              
BGI Genomics | Oncology assay interpretation services                
Revenue recognized         $ 300 $ 100    
Revenue, remaining performance obligation               $ 20,000